Novartis AG Common Stock (NY:NVS)

140.79 UNCHANGED

Delayed Quote Updated: 7:00 PM EDT, Oct 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Novartis AG Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

45 46 Next >

Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy? ↗

October 01, 2026

Investors are catching on to this rare gem among pharmaceutical stocks, but thanks to promising growth and a low valuation, further upside remains.

Via The Motley Fool

Novartis (NYSE:NVS) Offers Dividend Investors a Quality Income Profile ↗

September 26, 2026

Via Chartmill

Where Will CRISPR Therapeutics Be in 10 Years if Gene Editing Fulfills Its Promise? ↗

September 17, 2026

With a medicine on the market and plenty of projects in the pipeline, this company's trajectory could be very positive for investors without being a smooth ride.

Via The Motley Fool

Worried About a Market Crash? This Dividend Stock Outperformed as the S&P 500 Sank in Both 2008 and 2022 ↗

September 16, 2026

The pharmaceutical giant's track record in past bear markets is fairly impressive.

Via The Motley Fool

Novartis (NYSE:NVS): A Dividend Quality Play for Income Investors ↗

August 21, 2026

Via Chartmill

Novartis Suffers Another Setback After Two High-Profile Surprises Hammered Shares ↗

September 16, 2026

Novartis added another failure to its docket Wednesday, dropping an experimental treatment for the muscle-wasting disease.

Via Investor's Business Daily

VanEck Pharmaceutical ETF vs VanEck Biotech ETF: Which Fund Is Better for Drug Innovation Profits? ↗

September 15, 2026

PPH offers higher income and lower volatility, while BBH delivers stronger growth but with deeper drawdowns.

Via The Motley Fool

Topics ETFs

Novartis Just Shook Up a Multibillion-Dollar Drug Race. What It Means for Eli Lilly Stock. ↗

September 14, 2026

Lilly may be impacted by Novartis' pelacarsen flop -- but not by much.

Via The Motley Fool

Amgen Drops 10% on a Trial It Didn't Even Run ↗

September 11, 2026

AMGN stock fell after Novartis' Pelacarsen trial failed, though Amgen's own Olpasiran and Repatha differ in mechanism and results, and analysts have kept price targets largely intact.

Via MarketBeat

Top Investor Urges Novartis for Stronger Acquisition Oversight After M&A and Trial Setbacks ↗

September 11, 2026

Artisan Partners calls on Novartis to revamp board governance and acquisition oversight following sharp stock declines after trial setbacks.

Via Benzinga

Stock Market Today, Sept. 8: Stocks Slide Amid Surging Oil Prices, Persistent Geopolotical Tenisons ↗

September 08, 2026

Crude oil pushed toward $100 per barrel amid Middle East conflict and U.S.-Canada trade friction, today, Sept. 8, 2026.

Via The Motley Fool

Topics Artificial Intelligence Stocks World Trade

A Rivals Clinical Stumble Sends Sarepta Therapeutics Stock Lower ↗

September 08, 2026

Sarepta Therapeutics shares react to Novartis Phase 3 trial results in DM1 while Sarepta progresses its SRP-1003 RNA therapy clinical trials.

Via Benzinga

Novartis Myotonic Dystrophy Trial Flop Sends Dyne Therapeutics Shares Tumbling ↗

September 08, 2026

Dyne Therapeutics stock sinks on Novartis' failed Phase 3 myotonic dystrophy study, even as Dyne prepares new trial data presentations.

Via Benzinga

How Novartis And Ionis' High-Profile Failure Reverberated Through Biopharma ↗

September 08, 2026

Novartis and Ionis' high-profile Lp(a) flop on Friday reverberated through biotech stocks on Tuesday.

Via Investor's Business Daily

Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session ↗

September 08, 2026

U.S. stock futures fell as Novartis plunged 12.7% after pelacarsen’s Phase III trial missed its endpoint; other biotech stocks also declined.

Via Benzinga

Novartis Stock Drops as Trial Failures Ripple Across Biotech Partners ↗

September 08, 2026

Novartis stock falls following Phase 3 clinical trial failures for del-desiran and pelacarsen, impacting Ionis and Royalty Pharma shares.

Via Benzinga

United Natural Foods, ABM Industries and 3 Stocks to Watch Heading Into Tuesday ↗

September 08, 2026

Stocks in focus: UNFI and ABM earnings, Novartis trial miss, Co-Diagnostics CFO change, and Casey’s earnings expected.

Via Benzinga

Novartis, Ionis Tumble On Surprise Flop For Heart Drug ↗

September 04, 2026

Novartis' Ionis-partnered Lp(a) blocker failed in testing. Both stocks fell.

Via Investor's Business Daily

A Wall Street Analyst Spotted the Trial Freeze—Then Came News of Three Deaths ↗

September 04, 2026

Novartis and Bristol Myers pause CAR-T autoimmune trials after patient deaths and severe side effects spark safety concerns.

Via Benzinga

Topics Death

The Multiple Sclerosis Drug Race Just Got Hotter After Novartis’ Phase 3 Win ↗

September 01, 2026

Novartis stock spikes 5% on positive Phase 3 REMODEL trial results for relapsing MS drug remibrutinib with no liver safety signals.

Via Benzinga

Tuesday's session: gap up and gap down stocks ↗

September 01, 2026

Via Chartmill

Why Novartis Just Surged 6%, Eyeing A Breakout ↗

September 01, 2026

Novartis stock surged early Tuesday after its experimental multiple sclerosis treatment succeeded in a pair of midstage studies.

Via Investor's Business Daily

VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You? ↗

August 23, 2026

Vanguard offers three dividend ETFs—VIG, VYM, and VYMI—with distinct yields, holdings, and geographic focus, giving income investors varied ways to access dividend-paying stocks.

Via MarketBeat

Topics ETFs

Breakfast News: A Conversation With Ionis CEO ↗

August 22, 2026

Ionis Pharmaceuticals CEO on a major profitability milestone, breakthrough medicines and more.

Via The Motley Fool

Topics ETFs World Trade

Which Healthcare ETF Is the Better Buy: VanEck's Pharma PPH or State Street's Biotech XBI? ↗

August 18, 2026

PPH offers the income and stability of proven pharmaceutical leaders while XBI swings for the fences across 155 smaller biotech names.

Via The Motley Fool

Topics ETFs

PPH vs. IYH: Which Healthcare Fund Is the Better Buy? ↗

August 18, 2026

PPH concentrates on just 26 drugmakers, while IYH diversifies more broadly across 100 healthcare holdings.

Via The Motley Fool

Topics ETFs

This ETF Is Outperforming by Avoiding the S&P 500’s Biggest Problem ↗

August 17, 2026

The JPMorgan International Value ETF (JIVE) has outpaced the S&P 500 this year, offering low-volatility, diversified international exposure with a 1.22% yield and rising institutional demand.

Via MarketBeat

Topics Artificial Intelligence ETFs Stocks

The L.A. Lakers Delivered a 1-Year Return of 25%. These ETFs Have Done Even Better. ↗

August 16, 2026

Most people don't have $12.5 billion to buy the L.A. Lakers. But with stock ETFs, you could earn a higher return than the Lakers' owners.

Via The Motley Fool

Topics Artificial Intelligence ETFs Economy

Vanguard Is Bullish on Developed Markets Outside the U.S. -- But How Can You Buy Them? These 2 ETFs Can Help. ↗

August 14, 2026

Want to put your money into global stocks that might be big winners from AI? These two low-cost ETFs offer international diversification.

Via The Motley Fool

Topics Artificial Intelligence ETFs Economy

VanEck Pharmaceutical ETF vs. Invesco Biotech ETF: Which Fund Fits Your Investing Style? ↗

August 12, 2026

VanEck targets established pharma giants with lower costs and volatility, while Invesco pursues high-growth biotech companies. One delivered stronger returns; the other weathered downturns better.

Via The Motley Fool

Topics ETFs

< Previous 1 2 3 4 5 6 7 8 9

...

45 46 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.